Netosis in the pathogenesis of antiphospholipid syndrome and systemic lupus erythematosus
https://doi.org/10.14412/1996-7012-2021-5-96-102
Abstract
Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are autoimmune diseases. In recent years, APS has been considered as an autoimmune thrombo-inflammatory disease. It has been established that clinical manifestations of APS can persist, progress over time, or debut during an adequate anticoagulant therapy and, in some cases, require administration of immunosuppressive drugs, which indicates the role of autoimmune inflammation in their development. The formation of extracellular neutrophil traps (neutrophil extracellular traps, NETs) is one of the connecting links of inflammation and thrombosis. Netosis is the process by which activated neutrophils in the extracellular space form netlike structures (NETs). This review examines the role of neutrophils and netosis in the pathogenesis of APS and SLE.
Keywords
netosis,
extracellular neutrophil traps,
thrombus inflammation,
antiphospholipid syndrome,
systemic lupus erythematosus
Supporting agencies: The investigation has been conducted within scientific topic №АААА-А19-119021190151-3 «Development of methods for personalized therapy of rheumatic diseases with comorbid pathology».
About the Authors
K. S. Nurbaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
References
1. Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71. (In Russ.).
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.
3. Nasonov EL, editor. Systemic lupus erythematosus. In: Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTARMedia; 2017. P. 113-41.
4. Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016 Jun;3(2):75-84. doi: 10.5152/eurjrheum.2015.0085. Epub 2015 Dec 29.
5. Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thromb J. 2015 Apr 23;13:16. doi: 10.1186/s12959-015-0043-3. eCollection 2015.
6. Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG.et.al. Venous and Arterial Thrombotic Events in Systemic Lupus Erythematosus. J Rheumatol. 2016 Mar;43(3):576-86. doi: 10.3899/jrheum.150506
7. Al-Homood IA. Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol. 2012;2012:428269. doi: 10.5402/2012/428269. Epub 2012 Jul 30.
8. Cervera R, Serrano R, Pons-Estel GJ, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015 Jun; 74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838
9. Wirestam L, Arve S, Linge P, Bengtsson AA. Neutrophils-Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Front Immunol. 2019 Nov 22;10:2734. doi: 10.3389/fimmu.2019.02734. eCollection 2019.
10. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013 Jan;13(1):34-45. doi: 10.1038/nri3345. Epub 2012 Dec 7.
11. Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immuno-inflammatory rheumatic diseases: at the intersection of thromboinflammation and autoimmunity problems. Nauchno-prakticheskaya revmatologiya. 2020;58(4):353-67. (In Russ.).
12. Taraborelli M, Andreoli L, Tincani A. Much more than thrombosis and pregnancy loss: The antiphospholipid syndrome as a «systemic disease». Best Pract Res Clin Rheumatol. 2012 Feb;26(1):79-90. doi: 10.1016/j.berh.2012.01.006.
13. Yazici A. Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome. Eur J Rheumatol. 2020;7(4):180-3. doi:10.5152/eurjrheum.2020.20099
14. Xourgia E, Tektonidou MG. Management of Non-criteria Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2020 Jul 22;22(9):51. doi: 10.1007/s11926-020-00935-2.
15. Решетняк ТМ, Чельдиева ФА, Нурбаева КС и др. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;(4):4-21. [Reshetnyak TM, Chel'dieva FA, Nurbaeva KS, et al. Antiphospholipid syndrome: diagnosis, mechanism of development, therapy issues. Tromboz, gemostaz i reologiya. 2020;(4):4-21. (In Russ.)].
16. Andryukov BG, Bogdanova VD, Lyapun IN. Phenotypic heterogeneity of neutrophils: new antimicrobial characteristics and diagnostic technologies. Gematologiya i transfuziologiya. 2019;64(2):211-21. (In Russ.).
17. Hassani M, Hellebrekers P, Chen N, et al. On the origin of low-density neutrophils. J Leukoc Biol. 2020 May;107(5):809-18. doi: 10.1002/JLB.5HR0120-459R. Epub 2020 Mar 14.
18. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004 Mar 5;303(5663):1532-5. doi: 10.1126/science.1092385.
19. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol. 2012 Sep 15;189(6): 2689-95. doi: 10.4049/jimmunol.1201719.
20. Vorob'eva NV. Neutrophil extracellular traps: new aspects. Vestnik Moskovskogo universiteta. Seriya 16. Biologiya. 2020;75(4):210-25. (In Russ.).
21. Li Y, Wang W, Yang F, et al. The regulatory roles of neutrophils in adaptive immunity. Cell Commun Signal. 2019 Nov 14;17(1):147. doi: 10.1186/s12964-019-0471-y.
22. Minns D, Smith KJ, Findlay EG. Orchestration of Adaptive T Cell Responses by Neutrophil Granule Contents. Mediators Inflamm. 2019 Mar 10;2019:8968943. doi: 10.1155/2019/8968943. eCollection 2019.
23. Klopf J, Brostjan C, Eilenberg W, et al. Neutrophil Extracellular Traps and Their Implications in Cardiovascular and Inflammatory Disease. Int J Mol Sci. 2021 Jan 8;22(2):559. doi: 10.3390/ijms22020559.
24. Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2015 Sep;27(5):448-53. doi: 10.1097/BOR.0000000000000197.
25. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011 Sep 27;7(12):691-9. doi: 10.1038/nrrheum.2011.132.
26. Tay SH, Celhar T, Fairhurst AM. Low-Density Neutrophils in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Oct;72(10):1587-95. doi: 10.1002/art.41395.Epub 2020 Aug 26.
27. Rahman S, Sagar D, Hanna RN, et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. 2019 Jul;78(7):957-66. doi: 10.1136/annrheumdis-2018-214620. Epub 2019 Apr 30.
28. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011 Mar 9;3(73):73ra20. doi: 10.1126/scitranslmed. 3001201.
29. Van den Hoogen LL, van der Linden M, Meyaard L, et al. Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome. Ann Rheum Dis. 2020 Oct; 79(10):e135. doi: 10.1136/annrheumdis-2019-215781. Epub 2019 Jun 8.
30. De Bont CM, Boelens WC, Pruijn GJM. NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol. 2019 Jan;16(1):19-27. doi: 10.1038/s41423-018-0024-0. Epub 2018 Mar 23.
31. Hakkim A, Fü rnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010 May 25;107(21):9813-8. doi: 10.1073/pnas.0909927107. Epub 2010 May 3.
32. Leffler J, Gullstrand B, Jö nsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2013 Aug 14;15(4):R84. doi: 10.1186/ar4264.
33. Salemme R, Peralta LN, Meka SH, et al. The Role of NETosis in Systemic Lupus Erythematosus. J Cell Immunol. 2019;1(2): 33-42. doi: 10.33696/immunology.1.008.Epub 2019 Nov 12.
34. Lerner RG, Goldstein R, Cummings G, et al. Stimulation of human leukocyte thromboplastic activity by endotoxin. Proc Soc Exp Biol Med. 1971 Oct;138(1):145-8. doi: 10.3181/00379727-138-35848
35. Hirahashi J, Hishikawa K, Kaname S, et al. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation. 2009 Sep 29;120(13):1255-65. doi: 10.1161/CIRCULATIONAHA.109. 873695. Epub 2009 Sep 14.
36. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880-5. doi:10.1073/pnas.1005743107
37. Von Brü hl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012 Apr 9;209(4):819-35. doi: 10.1084/jem.20112322. Epub 2012 Mar 26.
38. Kambas K, Mitroulis I, Ritis K. The emerging role of neutrophils in thrombosis-the journey of TF through NETs. Front Immunol. 2012 Dec 18;3:385. doi: 10.3389/fimmu.2012.00385. eCollection 2012.
39. Barranco-Medina S, Pozzi N, Vogt AD, et al. Histone H4 promotes prothrombin autoactivation. J Biol Chem. 2013 Dec 13; 288(50):35749-57. doi: 10.1074/jbc.M113.509786. Epub 2013 Oct 30.
40. VarjЬ I, Longstaff C, Szabo L, et al. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost. 2015 Jun; 113(6):1289-98. doi: 10.1160/TH14-08-0669
41. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010 Aug;16(8):887-96. doi: 10.1038/nm.2184. Epub 2010 Aug 1.
42. Zuo Y, Kanthi Y, Knight JS, et al. The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Pract Res Clin Rheumatol. 2021 Mar;35(1): 101661. doi: 10.1016/j.berh.2021.101661. Epub 2021 Jan 13.
43. Yuen J, Pluthero FG, Douda DN, et al. Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Front Immunol. 2016 Apr 14;7:137. doi: 10.3389/fimmu.2016.00137. eCollection 2016.
44. Thalin C, Hisada Y, Lundströ m S, et al. Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer- Associated Thrombosis. Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1724-38. doi: 10.1161/ATVBAHA.119.312463.Epub 2019 Jul 18.
45. Laridan E, Martinod K, De Meyer SF. Neutrophil Extracellular Traps in Arterial and Venous Thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86-93. doi: 10.1055/s-0038-1677040
46. Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factorenriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020 Nov 2;130(11):6151-7.doi: 10.1172/JCI141374
47. Yalavarthi S, Gould TJ, Rao AN, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome.Arthritis Rheumatol. 2015 Nov;67(11): 2990-3003. doi: 10.1002/art.39247.
48. Meng H, Yalavarthi S, Kanthi Y, et al. In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. Arthritis Rheumatol. 2017 Mar;69(3):655-67. doi: 10.1002/art.39938
49. Zha C, Zhang W, Gao F, et al. Anti-β2GPI/β2GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. Neuropharmacology. 2018 Aug;138:140-50. doi: 10.1016/j.neuropharm.2018.06.001
50. You Y, Liu Y, Li F, et al. Anti-β2GPI/ β2GPI induces human neutrophils to generate NETs by relying on ROS. Cell Biochem Funct. 2019 Mar;37(2):56-61. doi: 10.1002/cbf.3363.Epub 2019 Jan 30.
51. Lu Y, Dong Y, Zhang Y, et al. Antiphospholipid antibody-activated NETs exacerbate trophoblast and endothelial cell injury in obstetric antiphospholipid syndrome. J Cell Mol Med. 2020 Jun;24(12): 6690-703. doi: 10.1111/jcmm.15321
52. Van der Linden M, van den Hoogen LL, Westerlaken GHA, et al. Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology (Oxford). 2018 Jul 1;57(7): 1228-34. doi: 10.1093/rheumatology/key067
53. Leffler J, Stojanovich L, Shoenfeld Y, et al. Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome. Clin Exp Rheumatol. Jan-Feb 2014;32(1):66-70. Epub 2013 Dec 2.
54. Zuo Y, Yalavarthi S, Gockman K, et al. Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. Arthritis Rheumatol. 2020 Dec;72(12):2130-5. doi: 10.1002/art.41460
55. Van den Hoogen LL, Fritsch-Stork RD, van Roon JA, Radstake TR. Low-Density Granulocytes Are Increased in Antiphospholipid Syndrome and Are Associated With Anti-β2 -Glycoprotein I Antibodies: Comment on the Article by Yalavarthi et al. Arthritis Rheumatol. 2016 May;68(5):1320-1. doi: 10.1002/art.39576
56. Mauracher LM, Krall M, Roiβ J, et al. Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals. Rheumatology (Oxford). 2021 Apr 6;60(4): 1687-99. doi: 10.1093/rheumatology/keaa532
57. Sule G, Kelley WJ, Gockman K, et al. Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac-1. Arthritis Rheumatol. 2020 Jan;72(1):114-124.doi: 10.1002/art.41057.
58. Knight JS, Meng H, Coit P, et al. Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. JCI Insight. 2017 Sep 21;2(18): e93897. doi: 10.1172/jci.insight.93897.
Review
For citations:
Nurbaeva KS, Reshetnyak TM, Lila AM. Netosis in the pathogenesis of antiphospholipid syndrome and systemic lupus erythematosus. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(5):96-102. (In Russ.) https://doi.org/10.14412/1996-7012-2021-5-96-102
Views:
940
Email this article 